Pretreatment CALLY Index and Survival Outcomes in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab: A Multicenter Retrospective Study
Murat Günaltılı1, Murad Guliyev1, Mehmet Cem Fidan1, Emir Çerme1, Vali Aliyev1, Şahin Bedir2, Nebi Serkan Demirci1, Özkan Alan11Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, Türkiye, 2Department of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul, Türkiye
Objectives: The C-reactive protein–albumin–lymphocyte (CALLY) index reflects systemic inflammation, nutritional status, and immune competence. We evaluated its prognostic value in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab in the second-line or later setting. Methods: This multicenter retrospective study included 181 patients receiving nivolumab monotherapy. The CALLY index was calculated from pretreatment albumin, absolute lymphocyte count, and C-reactive protein levels. Patients were divided into low and high CALLY groups using the cohort median. Progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan–Meier method, and independent prognostic factors were evaluated using Cox proportional hazards regression analyses. Results: Median follow-up was 27.6 months. Median PFS was shorter in the low CALLY group than in the high CALLY group (5.2 vs. 10.9 months; p=0.002), as was median OS (10.3 vs. 19.3 months; p<0.001). In multivariable analyses, a high CALLY index remained independently associated with longer PFS (HR 0.62, 95% CI 0.42–0.90; p=0.012) and OS (HR 0.47, 95% CI 0.31–0.72; p<0.001). Conclusion: The pretreatment CALLY index was independently associated with survival outcomes in patients with metastatic NSCLC treated with nivolumab and may be useful for prognostic
Cite This Article
Günaltılı M, Guliyev M, Fidan M, Çerme E, Aliyev V, Bedir Ş, Demirci N, Alan Ö. Pretreatment CALLY Index and Survival Outcomes in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab: A Multicenter Retrospective Study. EJMI. 2026; 10(3): 359-368
Corresponding Author: Murat Günaltılı